KN-93 (water soluble)
| Code | Size | Price |
|---|
| AG-CR1-0065-M001 | 1 mg | £50.00 |
Quantity:
| AG-CR1-0065-M005 | 5 mg | £120.00 |
Quantity:
| AG-CR1-0065-M025 | 25 mg | £340.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
2-[N-(2-Hydroxyethyl)-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine
Appearance:
White to off-white solid.
CAS:
1188890-41-6 | 139298-40-1 (free base)
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Hygroscopic.Protect from light.
InChi:
InChI=1S/C16H25NO2/c1-4-5-6-7-8-9-10-11-12-13-15(18)17-14-16(2,3)19/h4-9,12-13,19H,10-11,14H2,1-3H3,(H,17,18)/b5-4+,7-6+,9-8-,13-12+
InChiKey:
LHFKHAVGGJJQFF-UEOYEZOQSA-N
Long Description:
Chemical. CAS: 1188890-41-6 | 139298-40-1 (free base). Formula: C26H29ClN2O4S . H3PO4. MW: 501.0 . 98.0. Selective Ca2+/calmodulin-dependent protein kinase II inhibitor. Insulin release inhibitor. Acid secretion inhibitor. G1 cell cycle arrest inducer. Apoptosis inducer. Ion channel inhibitor. ROS inducer. Androgen receptor inhibitor.
MDL:
MFCD03788201
Molecular Formula:
C26H29ClN2O4S . H3PO4
Molecular Weight:
501.0 . 98.0
Other data:
Stock solutions are stable for up to 3 months when stored at -20°C.
Package Type:
Vial
Product Description:
Selective Ca2+/calmodulin-dependent protein kinase II inhibitor [1]. Insulin release inhibitor [2]. Acid secretion inhibitor [3]. G1 cell cycle arrest inducer [4]. Apoptosis inducer [4, 7]. Ion channel inhibitor [5, 6]. ROS inducer [7]. Androgen receptor inhibitor [7].
Purity:
>98% (HPLC)
SMILES:
OP(O)([O-])=O.COC1=CC=C(C=C1)S(=O)(=O)N(CCO)C1=C(C[NH+](C)CC=CC2=CC=C(Cl)C=C2)C=CC=C1
Solubility Chemicals:
Soluble in water.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells: M. Sumi, et al.; BBRC 181, 968 (1991) | Presence and possible involvement of Ca/calmodulin-dependent protein kinases in insulin release from the rat pancreatic beta cell: I. Niki, et al.; BBRC& 191, 255 (1993) | Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-93: N. Mamiya, et al.; BBRC 195, 608 (1993) | G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase): R.M. Tombes, et al.; Cell Growth Differ. 6, 1063 (1995) | CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium channels: L. Gao, et al.; BBRC 345, 1606 (2006) | KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels: S. Reazadeh, et al.; J. Pharmacol. Exp. Ther. 317, 292 (2006) | KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer: O.W. Rokhlin, et al.; Cancer Biol. Ther. 9, 224 (2010)